Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer

Detalles Bibliográficos
Autores principales: Yamaguchi, Teppei, Hida, Toyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798102/
https://www.ncbi.nlm.nih.gov/pubmed/35117056
http://dx.doi.org/10.21037/tcr.2019.12.57

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798102/
https://www.ncbi.nlm.nih.gov/pubmed/35117056
http://dx.doi.org/10.21037/tcr.2019.12.57

Ejemplares similares